Elenestinib

N/A

Report date: 2026/04/21 20:00:18
NME

Base Information

Drug NameElenestinib
Drug Alias NameBLU-263
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionStem cell growth factor receptor inhibitors
TargetsStem cell growth factor receptor
Therapy Area/IndicationsMastocytosis, Systemic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumUnited States +[18] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesBlueprint Medicines Corp
China Registration ClassN/A

Develop Information

Active CompaniesBlueprint Medicines Corp
Inactive CompaniesN/A
Active IndicationsMastocytosis, Systemic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A